Table 1 Characteristics of included studies and prevalence of FIBU
Items | Year | Country | Time period | Source of population | No. of scans | Detected FIBU* | ||
|---|---|---|---|---|---|---|---|---|
Studies | Female | Total | Female | Total | ||||
Chae et al. (2012) | 2012 | Korea | 2005–2010 | Patients with known or suspected malignancy or screening for malignancy | NR | 32,988 | NR | 131 (0.40) |
Kim et al. (2012) | 2012 | Korea | 2004–2010 | Patients underwent PET for staging of known primary malignancies or cancer screenings | NR | 5214 | NR | 27 (0.52) |
Dunne et al. (2013) | 2013 | Ireland | 2009–2012 | Patients underwent PET for any reason reporting breast abnormality | 2719 | 6050 | 50 (1.84) | 50 (0.83) |
Lim et al. (2013) | 2013 | Korea | 2006–2011 | Patients with known malignancy or asymptomatic women for their health check-up | 7594 | 43 (0.57) | ||
Minamimoto et al. (2015) | 2015 | Japan | 2006–2009 | Nationwide survey of the FDG-PET cancer screening program | 62,054 | 317 (0.51) | ||
Benveniste et al. (2015) | 2015 | USA | 2005–2011 | Patients underwent PET for any reason including the word “breast” in their report | 1866 | 1951 | 438 (23.5) | 438 (22.5) |
Bertagna et al. (2015) | 2015 | Italy | 2005–2013 | Patients underwent PET for oncologic purposes not related to breast disease | NR | 42,927 | NR | 79 (0.18) |
Shin et al. (2015) | 2015 | Korea | 2005–2011 | Patients underwent PET scans for cancer evaluation or health check-up | 21,224 | 214 (1.01) | ||